Telix Pharmaceuticals Limited (ASX: TLX)
Australia
· Delayed Price · Currency is AUD 24.85
+0.18 (0.73%)
Dec 31, 2024, 1:40 PM AEST
Telix Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Revenue | 645.68 | 502.55 | 160.1 | 7.6 | 5.21 | 3.49 | Upgrade
|
| Revenue Growth (YoY) | 80.92% | 213.90% | 2007.64% | 45.71% | 49.58% | 1687.18% | Upgrade
|
| Cost of Revenue | 240.33 | 188.16 | 65.17 | 2.55 | 2.02 | 2.54 | Upgrade
|
| Gross Profit | 405.35 | 314.39 | 94.93 | 5.05 | 3.19 | 0.94 | Upgrade
|
| Selling, General & Admin | 174.67 | 133.85 | 87.1 | 46.99 | 24.48 | 15.8 | Upgrade
|
| Research & Development | 164.31 | 128.84 | 81.01 | 34.14 | 23.09 | 21.16 | Upgrade
|
| Other Operating Expenses | -0.98 | -0.19 | 0.93 | - | - | - | Upgrade
|
| Operating Expenses | 338 | 262.5 | 169.03 | 86.3 | 52.44 | 41.2 | Upgrade
|
| Operating Income | 67.35 | 51.89 | -74.11 | -81.25 | -49.25 | -40.26 | Upgrade
|
| Interest Expense | -0.9 | -0.78 | -0.32 | -0.16 | -0.19 | -0.12 | Upgrade
|
| Interest & Investment Income | 1.94 | 1.02 | 0 | - | 0.07 | 0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.55 | -0.97 | -1.12 | 1.7 | -3.94 | -0.45 | Upgrade
|
| Other Non Operating Income (Expenses) | -15.43 | -12.99 | -6.37 | 14.1 | 12.11 | 11.88 | Upgrade
|
| EBT Excluding Unusual Items | 53.51 | 38.17 | -81.92 | -65.61 | -41.21 | -28.85 | Upgrade
|
| Asset Writedown | -0.8 | -0.8 | - | - | - | - | Upgrade
|
| Other Unusual Items | -1.29 | -34.28 | -16.71 | -14.86 | -6.73 | -2.27 | Upgrade
|
| Pretax Income | 50.07 | 3.09 | -98.62 | -80.47 | -47.94 | -31.12 | Upgrade
|
| Income Tax Expense | 0.88 | -2.12 | 5.46 | 0.05 | -3.05 | -3.26 | Upgrade
|
| Net Income | 49.19 | 5.21 | -104.08 | -80.51 | -44.89 | -27.87 | Upgrade
|
| Net Income to Common | 49.19 | 5.21 | -104.08 | -80.51 | -44.89 | -27.87 | Upgrade
|
| Shares Outstanding (Basic) | 324 | 319 | 311 | 282 | 257 | 233 | Upgrade
|
| Shares Outstanding (Diluted) | 334 | 324 | 311 | 282 | 257 | 233 | Upgrade
|
| Shares Change (YoY) | 5.90% | 4.21% | 10.08% | 9.69% | 10.21% | 15.49% | Upgrade
|
| EPS (Basic) | 0.15 | 0.02 | -0.34 | -0.29 | -0.17 | -0.12 | Upgrade
|
| EPS (Diluted) | 0.15 | 0.02 | -0.34 | -0.29 | -0.17 | -0.12 | Upgrade
|
| Free Cash Flow | 38.35 | 14.21 | -71.01 | -60.67 | 1.71 | -23.74 | Upgrade
|
| Free Cash Flow Per Share | 0.11 | 0.04 | -0.23 | -0.21 | 0.01 | -0.10 | Upgrade
|
| Gross Margin | 62.78% | 62.56% | 59.29% | 66.46% | 61.17% | 27.03% | Upgrade
|
| Operating Margin | 10.43% | 10.32% | -46.29% | -1069.60% | -944.81% | -1155.12% | Upgrade
|
| Profit Margin | 7.62% | 1.04% | -65.01% | -1059.90% | -861.06% | -799.63% | Upgrade
|
| Free Cash Flow Margin | 5.94% | 2.83% | -44.35% | -798.67% | 32.84% | -681.09% | Upgrade
|
| EBITDA | 73.14 | 57.17 | -69.59 | -76.73 | -44.94 | -36.27 | Upgrade
|
| EBITDA Margin | 11.33% | 11.38% | -43.47% | - | - | - | Upgrade
|
| D&A For EBITDA | 5.79 | 5.29 | 4.52 | 4.52 | 4.31 | 3.99 | Upgrade
|
| EBIT | 67.35 | 51.89 | -74.11 | -81.25 | -49.25 | -40.26 | Upgrade
|
| EBIT Margin | 10.43% | 10.32% | -46.29% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.